Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00373061 · ClinicalTrials.gov registry record
An Observational Study of the Use and Safety of Xolair® During Pregnancy
A clinical trial, sponsored by Genentech.
- Completed
- Registry status
- 309
- Enrollment target
NCT00373061: Completed study, sponsored by Genentech.
NCT00373061 is a clinical trial that has completed, run by Genentech. The registered enrollment target is 309 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00373061 has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- 309 participants
- Enrollment target
Study Summary
The Xolair® Pregnancy Registry is an observational study established by Genentech to obtain data on pregnancy outcomes in women who are exposed to Xolair®. Women exposed to at least one dose of Xolair® within 8 weeks prior to conception or at any time during their pregnancy will be followed to completion of their pregnancies. The evaluation of infants will be conducted at birth and at 6-month intervals until the infants are 12 months old. Follow-up of the infant will be extended until the infant is 18 months old, if the woman continues Xolair® treatment while breastfeeding.
Interventions
- DRUG Xolair®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 309 participants |
| Start Date | 2006-10-20 |
| Est. Completion | 2018-01-05 |
What the finished NCT00373061 record still lists
NCT00373061 is an observational study that tracks outcomes without assigning an intervention. The registered 309 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Xolair® is the first listed.
NCT00373061 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00373061 about?
NCT00373061 is a clinical study titled "An Observational Study of the Use and Safety of Xolair® During Pregnancy". The Xolair® Pregnancy Registry is an observational study established by Genentech to obtain data on pregnancy outcomes in women who are exposed to Xolair®. Women exposed to at least one dose of Xolair® within 8 weeks prior to conception or at any time during their pregnancy will be followed to compl...
What is the current status of trial NCT00373061?
This trial is currently completed. The enrollment target is 309 participants. The study started on 2006-10-20. Estimated completion is 2018-01-05.
What interventions are being tested in trial NCT00373061?
The interventions under investigation include: Xolair® (DRUG).
Who is sponsoring clinical trial NCT00373061?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03011684 · 309 participants · Phase 3
Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
- NCT06915233 · 309 participants · Phase 3
A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
- NCT03039439 · 310 participants
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
- NCT04178018 · 310 participants · NA
Transvaginal Ultrasound and Photoacoustic Imaging of Ovary
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI